Zobrazeno 21 - 30
of 214
pro vyhledávání: '"Alan Lau"'
Autor:
Kristoffer Valerie, Stephen T. Durant, Martin Pass, Kan Chen, Yingchun Wang, Tianwei Zhang, Li Zheng, Ian P. Barrett, Aaron Smith, Joanne Wilson, Nicola Colclough, Jason Kettle, Sebastien L. Degorce, Bernard Barlaam, Nitai Mukhopadhyay, Jason M. Beckta, Jenna Kahn, Laura Biddlestone-Thorpe, Nicholas C.K. Valerie, Amrita Sule, Thomas A. Hunt, Kurt G. Pike, Alan Lau, Jennifer Vincent, Bhavika Patel, Andrew G. Thomason, Antonio Garcia-Trinidad, Lucy C. Riches, Elaine B. Cadogan, Paul Farrington, Rajesh Odedra, Victoria Sheridan, Gareth Hughes, Syed F. Ahmad, Jasmine Allen, Jeremy Karlin
U87/Centrin2-EGFP/H2B-mCherry/puro cells were seeded on dishes with cover slip bottoms and irradiated (5 Gy). Time-lapse videos were recorded intermittently (every 7 min) over 16 hrs. Treatment results in 2.7% aberrant mitoses (see Fig. 3F).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8597de5b360dbd2701d63db0a2d2f9a5
https://doi.org/10.1158/1535-7163.22504758
https://doi.org/10.1158/1535-7163.22504758
Autor:
Yung-Jue Bang, Mark J. O'Connor, Alan Lau, Jeff Brown, Do-Youn Oh, Tae-Yong Kim, Jin Won Kim, Kyung-Hun Lee, Hee-Jun Kim, Yaewon Yang, Debora Keunyoung Kim, Miso Lee, Seongyeong Kim, Hyemin Jang, Seock-Ah Im, Ahrum Min
Anti-proliferative effects of AZD6738 on gastric cancer cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a294fb18544953c778147123aafaa4
https://doi.org/10.1158/1535-7163.22507600.v1
https://doi.org/10.1158/1535-7163.22507600.v1
Autor:
Duncan I. Jodrell, Frances M. Richards, Alan Lau, Sandra Bernaldo de Quirós Fernández, James W.T. Yates, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Charles R. Dunlop, Yann Wallez
Genetic alterations likely to sensitize to ATR inhibition in the human PDAC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ae5ee54dffa886a110e637a547155f5
https://doi.org/10.1158/1535-7163.22504491
https://doi.org/10.1158/1535-7163.22504491
Autor:
Kristoffer Valerie, Stephen T. Durant, Martin Pass, Kan Chen, Yingchun Wang, Tianwei Zhang, Li Zheng, Ian P. Barrett, Aaron Smith, Joanne Wilson, Nicola Colclough, Jason Kettle, Sebastien L. Degorce, Bernard Barlaam, Nitai Mukhopadhyay, Jason M. Beckta, Jenna Kahn, Laura Biddlestone-Thorpe, Nicholas C.K. Valerie, Amrita Sule, Thomas A. Hunt, Kurt G. Pike, Alan Lau, Jennifer Vincent, Bhavika Patel, Andrew G. Thomason, Antonio Garcia-Trinidad, Lucy C. Riches, Elaine B. Cadogan, Paul Farrington, Rajesh Odedra, Victoria Sheridan, Gareth Hughes, Syed F. Ahmad, Jasmine Allen, Jeremy Karlin
Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. A major impediment for clinical implementation is that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd6452a1cb4c3980123b06194a75b60c
https://doi.org/10.1158/1535-7163.c.6537843.v1
https://doi.org/10.1158/1535-7163.c.6537843.v1
Autor:
Yung-Jue Bang, Mark J. O'Connor, Alan Lau, Jeff Brown, Do-Youn Oh, Tae-Yong Kim, Jin Won Kim, Kyung-Hun Lee, Hee-Jun Kim, Yaewon Yang, Debora Keunyoung Kim, Miso Lee, Seongyeong Kim, Hyemin Jang, Seock-Ah Im, Ahrum Min
Ataxia telangiectasia and Rad3-related (ATR) can be considered an attractive target for cancer treatment due to its deleterious effect on cancer cells harboring a homologous recombination defect. The aim of this study was to investigate the potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f171db9087deba651e29c28f739d91a
https://doi.org/10.1158/1535-7163.c.6538738.v1
https://doi.org/10.1158/1535-7163.c.6538738.v1
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Supplementary Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddb28e2b040877b2021a52cb106bd7a
https://doi.org/10.1158/1078-0432.22489322
https://doi.org/10.1158/1078-0432.22489322
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Supplementary Figure from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4129939bd7a944921efb38cdb3344eaf
https://doi.org/10.1158/1078-0432.22489313.v1
https://doi.org/10.1158/1078-0432.22489313.v1
Autor:
Mark J. O'Connor, Judith Balmaña, Cristina Cruz, Christopher J. Lord, Elaine Cadogan, Josep V. Forment, J. Carl Barrett, Gordon B. Mills, Carlos Caldas, Brian Dougherty, Susan Critchlow, Alan Lau, Cristina Saura, Javier Cortés, Joaquin Arribas, Judit Grueso, Olga Rodríguez, Marta Guzman, Albert Gris-Oliver, Alejandra Bruna, Ambar Ahmed, Paul W.G. Wijnhoven, Adina Hughes, Zena Wilson, Jenni Nikkilä, Krishna C. Bulusu, Stephen J. Pettitt, Aditi Gulati, Rachel Brough, Alba Llop-Guevara, Filippos Michopoulos, Joshua Armenia, Zhongwu Lai, Gemma N. Jones, Andrea Herencia-Ropero, Marta Palafox, Urszula M. Polanska, Marta Castroviejo-Bermejo, Anderson T. Wang, Violeta Serra
Purpose:PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance mechanisms exist, most resulting i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292ea7f6a2f41a4ddcc686cb101c0beb
https://doi.org/10.1158/1078-0432.c.6532931.v1
https://doi.org/10.1158/1078-0432.c.6532931.v1
Autor:
Mark J. O'Connor, Alan Lau, Keith W. Caldecott, Niall M.B. Martin, David Rudge, Jos Jonkers, Sven Rottenberg, Marina Pajic, Robert H. Bradbury, Attilla Ting, Bastiaan Evers, Charlotte Knights, Louise Jones, Janneke E. Jaspers, Henry Brown, Rajesh Odedra, Aaron N. Cranston, Stuart L. Rulten, Lenka Oplustil O'Connor
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2109b65c80b64c5dc8e0c07cc7793822
https://doi.org/10.1158/0008-5472.c.6508109
https://doi.org/10.1158/0008-5472.c.6508109
Autor:
C. Blake Gilks, Yuzhuo Wang, David G. Huntsman, Mark J. O'Connor, Aaron N. Cranston, Alan Lau, Sharaz Shafait, Sophie Tully, Gavin Ha, Jun Guan, Hui Xue, Jessica N. McAlpine, Ursula Kortmann
Purpose: Most patients with ovarian carcinomas succumb to their disease and there is a critical need for improved therapeutic approaches. Carcinomas arising in BRCA mutation carriers display defective DNA double-strand break repair that can be therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30531f96fda83691f36466fbbce11e5e
https://doi.org/10.1158/1078-0432.c.6518824
https://doi.org/10.1158/1078-0432.c.6518824